The introduction of antibiotics nearly 100 years ago was and remains one of the most transformative advances of medicine and public health, and was followed by a prolific stream of new antibiotics, representing a variety of different antibacterial target classes, for the next several decades. However, since the early 2000’s, few new antibiotics have been introduced, a consequence of a dramatic decrease in investment by the pharmaceutical industry in antibiotic research and development.
In the meantime, according to the U.S. Centers for Disease Control and Prevention, an increasing number of bacteria have become resistant to currently available antibiotics. Without new antibiotics, we risk reversing one of the greatest triumphs of medicine and a return to the pre-antibiotic era, when common infections were untreatable and often fatal. Already in the United States at least two million people annually acquire serious bacterial infections that are resistant to one or more antibiotics. Antibiotic-resistant infections also add considerable and avoidable costs to the United States healthcare system. According to the CDC’s Antibiotic Resistance Threat Report, the total estimated financial cost of antibiotic resistance to the United States may range as high as $20 billion in excess direct healthcare costs, with additional societal costs for lost productivity as high as $35 billion a year.
Antimicrobial Resistance Remains Costly… and Deadly
US HEALTHCARE COSTS
ADDITIONAL DAYS IN THE HOSPITAL
– Tom Frieden, MD MPH, CDC Director (March 2015)
SOURCE: CID, 2009, Arlington Medical Research (AMR)
Our mission is to meet the continually evolving threat of bacterial infections by discovering, developing, and commercializing a continual stream of novel antibiotics.
Important background information on the threat posed by resistant bacterial infections can be found here: